

**SCREEN, TREAT AND RETAIN METH-USING PEOPLE WITH OPIOID USE DISORDERS AT METHADONE**

**CLINICS (STAR-OM)**

**NIH R01 DA050486**

**NCT04706624**

**STUDY PROTOCOL**

**DATE: April 1<sup>st</sup>, 2022**

## Table of Contents

<b>ABSTRACT .....</b>	<b>3</b>
<b>BACKGROUND AND RATIONALE .....</b>	<b>4</b>
<b>AIMS .....</b>	<b>5</b>
<b>STUDY DESIGN .....</b>	<b>6</b>
<b>Settings.....</b>	<b>6</b>
<b>Study schedule .....</b>	<b>6</b>
<b>Participants .....</b>	<b>8</b>
<b>Randomization and Interventions.....</b>	<b>8</b>
<b>Definition of effectiveness measures.....</b>	<b>9</b>
<b>Economic evaluation .....</b>	<b>11</b>
<b>Ethnographic evaluation .....</b>	<b>11</b>
<b>Training and fidelity monitoring.....</b>	<b>11</b>
<b>Sample size determination .....</b>	<b>12</b>
<b>Data management.....</b>	<b>14</b>
<b>Data analysis .....</b>	<b>14</b>
<b>Oversight and Monitoring .....</b>	<b>16</b>
<b>Ethics and Confidentiality.....</b>	<b>17</b>
<b>Challenges and adaptations .....</b>	<b>18</b>

## ABSTRACT

Methamphetamine use could jeopardize the current efforts to address opioid use disorder and HIV infection. Evidence-based behavioral interventions (EBI) are effective in reducing methamphetamine use. However, evidence on optimal combinations of EBI is limited. This protocol presents a Type-1 effectiveness-implementation hybrid design to evaluate the effectiveness, cost-effectiveness of adaptive methamphetamine use interventions and their implementation barriers in Vietnam.

*Design:* Participants will be first randomized into two frontline interventions for 12 weeks. They will then be placed or randomized to three adaptive strategies for another 12 weeks. An economic evaluation and an ethnographic evaluation will be conducted alongside the interventions. *Participants:* We will recruit 600 participants in 20 methadone clinics. Eligibility criteria: 1) age 16+, 2) Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) scores  $\geq 10$  for methamphetamine use or confirmed methamphetamine use with urine drug screening; 3) willing to provide three pieces of contact information; 4) having a cell phone.

*Outcomes:* Outcomes are measured at 13-, 26- and 49-week and throughout the interventions. Primary outcomes include: (1) increase in HIV viral suppression; (2) reduction in HIV risk behaviors; and (3) reduction in methamphetamine use.

*COVID-19 response:* We developed a response plan for interruptions caused by COVID-19 lockdowns to ensure data quality and intervention fidelity.

## BACKGROUND AND RATIONALE

The global rise of methamphetamine use could jeopardize current intervention efforts to address the twin epidemics of opioid use disorder (OUD) and HIV infection. Use of methamphetamine is increasingly common among people with primary OUD. Prevalence of methamphetamine use disorders is increasing in Vietnam, raising concerns about increased risk of HIV infection and disruption of the substance use treatment systems, especially methadone programs. Methamphetamine use among people living with HIV could decrease retention in care, hinder medication adherence, accelerate viral replication, and further HIV disease progression. Other countries beyond South-East Asia encounter similar challenges. In low-and-middle-income countries, it is vital to identify cost-effective models of adapted evidence-based practices for addressing substance use disorders.

Although there are no approved pharmacological treatments for methamphetamine use, evidence-based behavioral interventions (EBI) such as motivational interviewing, contingency management, cognitive behavioral therapy, including Matrix model have shown efficacy in reducing methamphetamine use. However, we need to identify optimal combinations of EBI for effectiveness and cost-effectiveness as many people in treatment face challenges to retention and sustained reductions in use.

*Motivational Interviewing.* Motivational interviewing helps individuals to evaluate the pros and cons to change drug use and to develop personalized change behaviors. Motivational interviewing can be used in a single session or in multiple sessions. Polcin et al. (2014) compared two motivational interviewing conditions (9 sessions vs. 1 session) and found that both groups showed significant reductions in methamphetamine use without differences between the two groups. A greater reduction in psychiatric symptoms including anxiety and depression was found among those receiving more motivational interviewing sessions.

*Contingency Management.* Contingency management has shown the strongest evidence in treating methamphetamine use disorders. It is also effective in reducing other drug use including alcohol, cannabis, nicotine and opioids. Contingency management is based on the theory of operant conditioning where incentives are used to strengthen the target behavior such as abstinence, reduction of sexual risk behaviors or other health-promoting behaviors like retention or adherence to treatment. Contingency management effects are enhanced in combination with other psychosocial interventions or education. A recent meta-analysis shows contingency management is more efficacious than other EBI up to one year following the discontinuation of reinforcers.

*Matrix Model.* The Matrix model has shown greater reduction in methamphetamine use, risky behaviors and more days of abstinence compared to non-standardized outpatient treatment

approaches. This intervention combines different elements of effective approaches including cognitive and behavioral treatment using accurate information on the effects of stimulants, relapse prevention skills training, 12-step program participation and family education. Its manualized treatment protocol ensures fidelity when the model is implemented in different settings.

*SMS Text Messages.* Using SMS text messages with people who use methamphetamine has been shown to reduce methamphetamine use and HIV-related sexual transmission behaviors, and increase retention in HIV care among some key populations. Scripted unidirectional texts outperform bidirectional interactive text-messaging conversations in reducing methamphetamine use and HIV sexual risk behaviors, and are more cost-effective than in-person therapies. Theory-driven messaging might better benefit people in the early stages of behavior change (e.g. non-treatment seeking participants) than people who are already seeking help.

Despite some demonstrated efficacy, few studies have shown ways to optimize and combine treatment approaches for methamphetamine use disorders. Qualitative reports show patients found contingency management beneficial when combined with motivational interviewing and cognitive behavioral techniques for methamphetamine use disorders. Combined motivational interviewing and cognitive behavioral treatment show efficacy in reducing methamphetamine use in HIV-positive MSM. Evidence supports combining psychosocial treatment with medication-assisted treatment in people with OUD, but it is unclear whether patients with comorbid methamphetamine use disorder will experience similar benefits.

Integrating screening and brief interventions, contingency management or conditional cash transfer, and cognitive behavioral therapy for the management of substance use disorders requires trained health professionals. This is challenging in settings where human resource for mental health/substance use is scarce. Therefore, besides identifying optimal combination of EBI, it is essential to recognize potential barriers to the implementation of these strategies. Our study, *‘Screen, Treat and Retain people with opioid use disorders who use methamphetamine in methadone clinics’* (STAR-OM) proposes to explore these questions.

## AIMS

The study has three aims:

**Aim 1:** To develop and to compare the effectiveness of two frontline interventions and four adaptive strategies in improving HIV and substance use outcomes among people with OUD who use methamphetamine at methadone clinics in the two largest cities in Vietnam.

**Aim 2:** To compare cost-effectiveness of two frontline interventions and of four adaptive strategies in improving both HIV and substance use outcomes among people with OUD who use methamphetamine at methadone clinics.

**Aim 3:** To identify the structural, provider, and patient-level factors that influence adoption and scale-up of the studied model in methadone clinics.

## STUDY DESIGN

The study deploys a Type-1 effectiveness-implementation hybrid design to evaluate the effectiveness of the proposed adaptive interventions and gather data on the implementation. To evaluate the effectiveness of the interventions, the study employs a Sequential Multiple Assignment Randomized Trial (SMART) design. In the first phase, participants will be randomized into two frontline interventions for 12 weeks. Based on their outcome at the end of this phase, they will be placed or randomized into three adaptive strategies for another 12 weeks (Figure 1). The economic evaluation that addresses Aim 2, aims to weigh public health and societal costs against public health and societal benefits attributed to the interventions of different intensities with a time horizon of 12 months. To address Aim 3, we will conduct an ethnographic evaluation to identify the multi-level factors that influence the adoption and scale-up of the interventions in methadone clinics. The ethnographic evaluation is guided by the Consolidated Framework for Implementation Research (CFIR). The CFIR assesses five domains of interventions, outer settings, inner settings, provider characteristics and participant characteristics. The evaluation includes pre- and post-intervention in-depth interviews with key informants who participate in the study and ethnographic observation with participants in their daily activities at the clinics and in the community settings.

## Settings


Participants are recruited from the methadone clinics in Hanoi and Ho Chi Minh City (HCMC) – the two largest urban settings in Vietnam. Criteria for selecting clinics include number of patients, estimated prevalence of methamphetamine use, availability of human resources to implement study interventions, and space for intervention activities. 10 clinics in each city will be randomly selected from those that meet the criteria.

## Study schedule

The study pilot phase started in November 2020. The full study implementation phase began in May 2021. To recruit 200 HIV-positive and 400 HIV-negative methamphetamine-using methadone participants from both cities, we will screen about 5,000 patients in 20 methadone clinics. A cluster

of four methadone clinics will start every six months. We expect to complete the last cluster in October 2023.

*Figure 1. Study flowchart*



## Participants

### **1.1. Participants under methadone treatment**

We will recruit 600 methadone participants with the following eligibility criteria: 1) age 16 or older, 2) Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) scores 10 or more for methamphetamine use or confirmed methamphetamine use with urine drug screening (UDS); 3) willing to provide at least three pieces of contact information; 4) has a cell phone that can receive text messages. The criteria of ASSIST scores and UDS had been modified after the pilot implementation (see Section 14.2.1). Exclusion criteria are: 1) psychosis or other interfering problems; 2) inability to understand study procedures by research assistants' judgment. While World Health Organization recommends the ASSIST score of 4 or more, regardless of UDS, as a cut-off point for interventions, drawing from the results of the pilot phase we have chosen the cut-off point of ASSIST score 10 or more to ensure enough participants move into the adaptive phase.

### **1.2. Methadone providers**

Methadone providers will conduct the study interventions under the clinical supervision of the study master counselors. All methadone providers have been trained on basic addiction medicine and will receive further training to deliver the study interventions. We will conduct in-depth interviews with them before and after the intervention phase.

## Randomization and Interventions

An investigator will stratify participants by HIV status and randomize them into two frontline interventions using REDCap, as shown in Figure 1. She will send the allocation results to the site research assistants who will then inform providers at the study clinics. This is an open label study so unblinding does not occur. Participants and their counselors, research assistants and data managers are aware of participants' assignment of intervention. Participants will receive two individual sessions of motivational interviewing with their counselors before they get into the frontline interventions and, in Week 13, before the adaptive strategies start. These sessions would boost participants' motivation for intervention and provide them with greater details of the upcoming intervention activities.

### **Two frontline interventions (Weeks 1-12)**

- High intensity: Participants in this arm receive contingency management with the escalating-and-reset schedule throughout 12 weeks. This schedule means participants receive increasing rewards for consecutive negative UDS but if the streak of negative UDS is broken,



their rewards return to the starting level. The maximal reward value over 12 weeks is \$150 USD, equivalent to the average monthly income of our participants.

- Low intensity: Participants in this arm receive contingency management for the first six weeks with the maximal reward value of \$40 USD. For the last six weeks, they attend weekly group education sessions. The topics of group education include 1) Addiction mechanism, 2) Road to recovery, 3) Coping with triggers, 4) Boredom, 5) Building trust and 6) Relapse prevention.

Participants with four consecutive UDS negative with methamphetamine in weeks 11 and 12 are considered to be responsive to frontline interventions. Others are considered non-responsive. Responders to frontline interventions are placed in the maintenance treatment arm. Non-responders are randomized to either enhanced treatment 1 or 2.

### ***Three adaptive strategies (Weeks 14-25)***

- Maintenance treatment: Participants receive two daily automatic unidirectional scripted SMS reminders plus one weekly self-monitoring assessment message over 12 weeks.
- Enhanced treatment 1: Participants attend 12 weekly Matrix group counseling sessions facilitated by the clinic counselors. Our Matrix intervention has the same structure, albeit it is shorter than the original 24-sessions model.
- Enhanced treatment 2: Participants receive the same Matrix intervention plus contingency management over 12 weeks.

### **Definition of effectiveness measures**

Effectiveness measures will be assessed at 13-, 26- and 49 weeks after the first week of frontline interventions and throughout the interventions. Primary outcomes include: (1) increase in HIV viral suppression for HIV-positive participants at 26- and 49-weeks; (2) reduction in HIV risk behaviors for both HIV-positive and HIV-negative participants at 26- and 49-weeks; and (3) reduction in methamphetamine use at 13-, 26- and 49-weeks measured by UDS (point abstinence) and self-report (continuous abstinence and longest period). Secondary outcomes include: (1) adherence to antiretroviral treatment for HIV-positive participants; 2) frequency of HIV testing for HIV-negative participants; 3) heroin use with UDS; 4) opioid overdose; and, 5) quality of life.

To acquire the primary and secondary outcomes, we will assess for the following:

- HIV viral load test. At baseline, Week 13, Week 26 and Week 49, we send blood samples of HIV-positive participants to laboratories at Bach Mai Hospital in Hanoi and HCMC University of Medicine and Pharmacy Hospital in HCMC for viral load quantification.

- Drug screening. We use an FDA-approved Multi-Drug Rapid Test Panel to detect methamphetamine, opioid, and cannabis in urine twice a week throughout the intervention period and at Week 49.
- Methadone and HIV treatment. We extract methadone and HIV treatment data from participants' medical charts. Variables of interest include length of treatment, treatment regimen, medication dose and treatment adherence.
- Self-reported drug use. Drug use patterns (methamphetamine, tobacco and alcohol use) are evaluated based on amphetamine use behaviors, Amphetamine Cessation Symptom Assessment (ACSA), Addiction Severity Index (ASI) and Alcohol Use Disorders Identification Test-Concise (AUDIT-C) scales. ACSA, a 5-point Likert scale has been used in other studies in Vietnam. The scale includes three domains of methamphetamine withdrawal symptoms: fatigue (3 items), cravings (2 items) and anxiety (11 items). Higher scores in each domain and in total indicate greater levels of methamphetamine withdrawal symptoms. AUDIT-C is used for identifying patients who drink at hazardous levels or have active alcohol use disorders. AUDIT-C comprises 3 questions scoring on a scale of 0-12 with a cut-off point of 4 for men and of 3 for women.
- Self-reported psychosocial factors. We use the Barriers to Access to Care Evaluation (BACE) scale to assess barriers to access to mental health care (58). Participants are asked to what extent they agree or disagree with statements indicating barriers to mental health care. We use the 21-item Depression, Anxiety, Stress Scale (DASS-21) which was previously validated in Vietnam to measure mental health. The DASS-21 scale consists of 7 Likert items for each dimension (depression, anxiety and stress). For each item, respondents indicate how often it applies to them over the past week. The total score of each dimension will indicate the severity level of depression, anxiety and stress. The Medical Outcome Study: Social Support Survey scale (MOS-SSS), also validated in Vietnam, is used to measure social support. The MOS-SSS comprises 19 items covering four domains: emotional/informational support, tangible social support, positive social interaction, and affectionate support. Higher scores suggest greater support received. Quality of life is measured with the EQ-5D-5L scale which includes the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (VAS). The descriptive system covers 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). On the EQ VAS, respondents indicate the score that represents their health status on the scale that ranges from 0 (the worst health they can image) to 100 (the best health they can image). The EQ-5D-5L was previously validated in Vietnam.

## Economic evaluation

### ***Definition of costs and data collection***

We will conduct activity-based costing for each intervention arm over the 20 methadone clinics. A template developed by UNAIDS is adapted to collect data on salaries for personnel and consultants, physical resources, clinical supplies and miscellaneous charges necessary to deliver each intervention type. Furthermore, any out-of-pocket or indirect costs to the participant will be collected at baseline, and at 13- and 26-week.

### ***Definition of cost-effectiveness measures***

Measures of cost-effectiveness analysis corresponded to the outcomes of interest in Aim 1 including (1) Substance use, (2) HIV risk behaviors among HIV-negative participants and HIV viral load, HIV adherence among HIV-positive participants and (3) Quality of life (Table 1). The cost-effectiveness analysis will measure the increment in cost between contrasted interventions divided by the increment in effectiveness measures.

## Ethnographic evaluation

### ***Pre-post intervention in-depth interviews***

In each cluster, we will interview 12 key informants including methadone providers, clinic managers and participants under methadone treatment participating in the study. We will select at minimum 6 participants under treatment so that include old and young, employed and unemployed, and both responsive and non-responsive participants. All participants will receive VND 200 000 (~\$10 USD) for their time in each interview. Interviews will be audio-recorded and transcribed verbatim.

### ***Ethnographic observation***

This activity is composed of two elements. The first element involves ethnographers spending time with participants with their consent in intervention sessions and other daily activities in the clinic. Such observations will build a rich picture of interventions and intervention settings, including interactions between various groups (intervention providers, other staff, and participants). The second element involves the study master counselors to observe random intervention sessions and assess the fidelity of intervention delivery using a checklist.

## Training and fidelity monitoring

In each selected clinic, a physician, two counselors and one nurse will participate in the study as intervention providers. The physician will ensure referral to HIV and psychiatric services when

necessary; two counselors will run motivational interviewing, group education sessions and Matrix meetings; the nurse will collect urine twice a week and conduct contingency management based on the UDS results. Before the start of the intervention, to ensure the accuracy, integrity and fidelity to the EBIs, all intervention staff at methadone clinics will (1) receive didactic training on the theory behind the approach; (2) evaluate their comprehension of the concepts within and behind the approach; (3) watch a video of a Master Behavioral Counselor conducting intervention sessions and discuss the details of the session, and (4) conduct at least two pilot intervention instances. All intervention sessions, except contingency management, will be audio recorded, transcribed, and coded to ensure intervention fidelity. Intervention staff who have lower levels of intervention integrity or who have significant drift will be provided detailed feedback and supervision until there is parity with other staff.

### Sample size determination

Sample sizes were chosen to compare primary outcomes based on first-stage randomization into one of two groups: high intensity or low intensity frontline interventions. Sample size calculations are conducted in PASS 2008 (65) for a two-group comparison of binary outcomes, a power of 80%, a 5% alpha level, and a conservative attrition rate of 20%. Using estimates from our prior work, we anticipate base rates of 80% to 90% for substance use and 60% to 70% for viral suppression. Based on these assumptions and a proposed sample of 200 HIV-positive participants (with 100 participants per group), we can detect randomization group differences of 20% or more for binary outcomes, such as substance use and viral load suppression. We can detect even smaller group differences for substance use outcomes in the proposed sample of 400 HIV-negative participants and the combined sample of HIV-positive and negative participants. If estimated outcome probabilities are similar between first-stage randomization groups at 12 weeks, we will pool 12-week results for even greater power in evaluating second-stage randomization differences.

*Table 1. Assessment schedule*

<b>Assessments</b>	<b>Baseline</b>	<b>Week 13</b>	<b>Week 26</b>	<b>Week 49</b>
<b>Sociodemographic characteristics</b>	X			X
<b>Drug use history</b>	X		X	X
<b>Current drug use</b>	X		X	X
Amphetamine use behaviors				
Amphetamine Cessation Symptom Assessment (ACSA)				

<b>Tobacco smoking</b>	X		X	X
<b>Alcohol use</b> AUDIT-C	X		X	X
<b>Barriers to access to care</b> BACE	X		X	X
<b>Mental health</b> Depression, Anxiety, Stress Scale (DASS-21)	X		X	X
<b>Social support</b> (MOS-SS)	X		X	X
<b>Quality of life</b> (EQ-5D-5L)	X			X
<b>Stigmatisation</b> Towards people who are under methadone treatment (MMT-SMS) Toward people who use drugs Toward people living with HIV	X			X
<b>Treatment information (from medical charts)</b> Methadone maintenance treatment HIV treatment	X	X	X	X
<b>Cost data</b> Opportunity costs Other healthcare costs Social costs	X		X	X
<b>Tests</b>				
Quick and confirmatory HIV tests (not for participants with known HIV seropositivity)	X	X	X	X
Viral load test	X	X	X	X
UDS	Twice a week throughout intervention			X
<b>Ethnographic observation</b>	X	X	X	X
<b>Qualitative interviews</b>	X		X	

## Data management

Different datasets collected from different sources will be linked through a unique identification code using REDCap (Research Electronic Data Capture) for quantitative data. Data will be uploaded in real-time from the 20 study clinics onto our database. The study data manager will assess transferred data for completeness, query sites regarding any inconsistencies, and code merged data files for analysis.

For qualitative data, field notes written on site are expanded and recorded electronically within 24 hours. After removing all personal identifiable information, the research team will upload password-protected transcripts on a secured database. The transcripts will be uploaded into Atlas.ti software to organize data and facilitate analysis.

## Data analysis

### ***To assess effectiveness***

We will use a time-varying mixed-effects model that will be fitted to the participants' common outcome measures over time. The unadjusted model will include indicators of first-stage and second-stage intervention conditions, time of the assessment (baseline, 13-, 26-, and 49-weeks), and intervention indicators-by-time interaction terms. An additional interaction term of the two intervention indicators will be included to account for any interaction effect between the first and the second stage interventions. The adjusted model will include patients' socio-demographic characteristics, drug use history, HIV-serostatus, and location as fixed effects. The mixed-effects models will include a participant-level random effect to account for repeated observations of each participant, as well as a clinic-level random effect to account for the nested nature within the clinics. We will conduct subgroup analyses among HIV-positive and HIV-negative participants. For the HIV-positive subgroup, the specific outcomes of interest include 1) HIV viral load suppression, and 2) adherence to antiretroviral treatment; and specific outcomes for HIV-negative subgroup include 1) frequency of HIV testing and 2) HIV seroconversion. Substance use will be the common outcomes in models including participants of both HIV statuses.

### ***To assess cost-effectiveness***

We will calculate Cost Effectiveness Ratios (CER) for each of the intermediate and final outcomes. The CER is in the broadest terms the difference in per capita costs of administering one intervention (C1-C2) relative to a second, divided by the difference in outcomes between the two interventions (O1-O2):

$$CER = \frac{C1 - C2}{O1 - O2}$$

For example, calculating the CER for adding contingency management to Matrix for non-responders would yield a CER equation. In calculating the CER of high vs. low intensity contingency management at the first randomization stage, the entire range of subsequent costs will be included. Costs of delivering the interventions will be derived from clinic records of time and other inputs, as well as incentive payments, thus providing an estimate of CER from the medical system perspective. We will also evaluate CERs from a societal perspective, using a broad definition of costs, including the social costs of incarceration.

We will conduct sensitivity analyses to estimate the extent to which the CER calculation is affected by differences in assumptions about the size of the differences in intervention effect. In particular, we will determine how sensitive the CER is to assumptions that the difference in treatment effect is one standard deviation below or above the mean estimated effect size. Similarly, we will estimate the sensitivity of conclusions to costs that are one standard deviation below or above the estimated mean.

#### ***To identify the factors influencing the adoption and scale up of the model***

The qualitative analysis team will read and provide a narrative summary for each transcript. A codebook will be developed based on these summaries. Memo-writing and code-refining will be conducted throughout the analysis. Iterative analyses assess convergence of patient, provider and organizational dimensions on study measures as well as the context of the policy subsystems, cross system interactions, and resource allocation.

#### ***Analysis of non-adherence and missing data***

We will first describe the extent and patterns of missingness within each variable, check for associations between missing and observed data to determine the mechanism of missingness, which could be missing completely at random, missing at random, or missing not at random. Missing data will then be handled using multiple imputation (68). Appropriate imputation techniques will be chosen for the type of missing data and the statistical tools employed (69). For sensitivity analysis, we will conduct analyses with and without multiple imputations. All participants will be analyzed on an intent-to-treat basis where the study outcomes are examined based on the random intervention assignment and not on the actual intervention received or adherence to the intervention.

#### ***Interim analyses***

There is no planned interim analysis as the behavioral therapies used in this trial have no known serious adverse events and are consistently more efficacious than control conditions in treatment-seeking participants. The effect sizes of the behavioral therapies in this trial are in the

moderate range. Furthermore, any interim analysis and decision to stop the trial would likely be based on underpowered data and susceptible to error.

## Oversight and Monitoring

### ***Scientific advisory committee***

The study scientific advisory committee members include researchers, policy makers and activists working in HIV and addiction medicine fields in the U.S. and Vietnam. The scientific advisory committee meets once a year to review research progress and key findings, as well as discuss challenges to study implementation and plans to solve these challenges.

### ***Data monitoring committee***

Our data monitoring committee is composed of members of the Data and Safety Monitoring Board for Addiction Medicine (DSMBAM) of the University of California – Los Angeles. These members are not connected to the study in any way. The DSMBAM is independent from the National Institute on Drug Abuse (NIDA) – the sponsor of this study. The DSMBAM meets quarterly to monitor subjects' progress in the trial and considers whether adverse social harms (e.g., police detention, hospitalization due to overdose) differentially accrue by condition. Although there are no prospective stopping rules for this trial, the DSMBAM is within its charge to review aggregate data, request statistical tests of differences in social or other harms, and then advise changes in intervention type or intensity if statistically significant differences emerge in adverse events by condition. Prior to each meeting, the study team will submit a performance report including all reports of SAEs for DSMBAM's consideration. After each meeting, recommendations will be made in writing to the principal investigators.

### ***Auditing trial conduct***

Hanoi Medical University and the staff in the STAR-OM study provide oversight of financial management. The Vietnam teams and U.S. teams maintain frequent communication via emails and bi-weekly online meetings to report updates on the study progress, discuss scientific aspects of the study, and troubleshoot issues when they arise. The teams in Hanoi and HCMC meet online once weekly and in-person quarterly during monitoring visits to discuss the study conduct. We submit annual research progress reports to the Ethics Committee of Hanoi Medical University. Any protocol amendments need to get ethical approval before implementation. The UCLA Addiction Medicine Data Safety Monitoring Board independently review our data and data management twice a year.

### ***Adverse event reporting and harms***



Adverse events in this trial are defined as medical issues that do not require hospitalization. Serious adverse events are defined as life-threatening events such (e.g. suicide, opioid overdose) or other events that have a negative impact on participants' life such as incarceration or compulsory drug rehabilitation. The clinic staff will communicate information about adverse events and serious adverse events to the study team right after they are informed by participants or participant families. The study coordinators in Hanoi and HCMC are responsible to report adverse events within 7 days and serious adverse events within 24 hours on REDCap with the time of onset, seriousness, duration, and outcomes. The principal investigator will decide what serious adverse events need to be reported to the Ethics Committee.

#### ***Plan for communicating important protocol amendment to relevant parties***

We will first seek advice of our scientific advisory committee for all protocol amendments. Protocol amendments will undergo the review of Ethics Committee. If they are approved, we will notify the trial funder about these amendments. No protocol modifications will be implemented without ethical approval. Notification of the approved modifications will be forwarded to all study team members.

#### ***Dissemination plans***

Results of this study will be published in peer-reviewed scientific articles and presented at international and regional conferences. We will organize dissemination workshops to communicate the study results to policy makers and healthcare professionals at the end of the trial. The de-identified datasets, statistical code, and full protocol are available from the first author upon reasonable request.

#### **Ethics and Confidentiality**

Prior to participation in the trial, the participant will be informed about the research. Participants will complete a short questionnaire about the study objectives and main activities to show how they understand the study. Research assistants will provide more explanation based on the results of the questionnaire. If participants agree to join the study, they will sign a consent form. Each participant will be assigned a unique identifier at the time of screening. Participant data will be linked to this identifier only. Participant personal identifiable information is stored in a separate locked cabinet to which only responsible study staff have access. All study staff sign a confidentiality agreement to non-disclosure of participant information. We make extra efforts to ensure no-disclosure of drug use information to anyone other than participants and the study staff.

*Provision of post-trial care:* Participants continue to receive usual methadone treatment at post-trial. While there is no formal provision of methamphetamine intervention after the trial

completes, the clinic staff with experiences in methamphetamine intervention would likely provide better service for participants in need.

## Challenges and adaptations

### ***Intervention adaptation***

Between July and October 2020, we conducted 4 focus group discussions (FGD) of a convenience sample of participants from four methadone clinics in the downtown and suburbs of Hanoi and HCMC to inform intervention content and refinement. Respondents reported information on local taxonomy and patterns of methamphetamine use, triggering situations, methamphetamine-related sexual risks, motivations for seeking treatment, and perceived acceptability of the adaptive interventions.

The pilot implementation lasted 12 weeks from November 2020 through February 2021. It identified issues to be addressed before the full implementation. At the conclusion of the pilot, we conducted 2 FGD with patients and 1 FGD with providers participating in the pilot to gauge their feedback about the interventions.

### ***Challenges and modifications***

#### Modification of eligibility criteria

With the cut-off point of ASSIST  $\geq 4$  and methamphetamine-positive UDS as originally proposed, there were 26 and 52 eligible participants in two pilot clinics in Hanoi and HCMC, respectively (see Table 2). For the pilot implementation, we randomly recruited 42 participants with ASSIST score  $\geq 4$  or methamphetamine-positive UDS. After the frontline intervention, 16 (38%) participants were non-responders and randomized into adaptive interventions. At least 50% of the original sample must transition to the adaptive phase for sufficient statistical power. Thus, we decided to recruit more participants with severe use of methamphetamine, as evidenced in both ASSIST score  $\geq 10$  and methamphetamine-positive UDS. Furthermore, to recruit enough participants for the frontline intervention phase, given most other clinics are smaller than the two pilot ones, we decided to use ASSIST score 'OR' UDS instead of 'AND' to increase the pool of potential participants. We kept the criterion of methamphetamine-positive UDS to compensate for participants with lower ASSIST scores due to desirability bias.

#### Modification to minimize the impacts of the COVID-19 pandemic

Since late April 2021, the COVID-19 epidemic in Vietnam was severe. HCMC applied a strict lockdown from early July 2021 through September 2021. Some methadone clinics were temporarily closed due to confirmed COVID-19 cases among patients, medications were delivered at community-

based healthcare centers. In the clinics that remained open, clinical activities other than medication dispensing ceased to minimize contact between providers and patients. Unlike HCMC, clinical activities in Hanoi continued, albeit at levels lower than pre-pandemic. In addition, methadone clinics in both cities suffered from staff shortages as many staff were deployed to support ongoing COVID-19 prevention and treatment activities. With advice of the study's Scientific Advisory Board, we developed a response plan to potential COVID-19 interruptions to minimize the pandemic's impact (see Figure 2).

**For intervention:**

- For group education and Matrix sessions, we will conduct small groups of five or fewer people during the surge of the COVID-19 pandemic when the city authorities forbid large meetings. If we cannot conduct group sessions, we will provide individual sessions of the same content to ensure all participants receive interventions.
- For participants who miss scheduled visits due to COVID-19, we will consider whether to resume the intervention where they left off or to restart their intervention phase. This will depend upon: 1) the length of the interruption (15 days or less); and, 2) whether participants have gone through 50% of their scheduled intervention sessions before the interruption.

Figure 2. Response plan to COVID-19 related interruptions

